Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40391923.
- Also identified by DOI 10.1093/cid/ciaf204 and PMC identifier 12596406.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
Medical subject headings
- Heterocyclic Compounds, 3-Ring
- HIV Infections
- Drug Resistance, Viral
- HIV Integrase Inhibitors
- HIV-1
- Viremia